1360430-70-1

Basic information

• Product Name: N-(3-chloro-4-fluorophenyl)-7-ethoxy-6-nitroquinazoline-4-amine
• Synonyms: N-(3-chloro-4-fluorophenyl)-7-ethoxy-6-nitroquinazoline-4-amine
• CAS NO: 1360430-70-1
• Molecular Weight: 362.748
• Mol File: 1360430-70-1.mol
• Article Data: 7

Chemical Properties

• CAS DataBase Reference: N-(3-chloro-4-fluorophenyl)-7-ethoxy-6-nitroquinazoline-4-amine(CAS DataBase Reference)
• NIST Chemistry Reference: N-(3-chloro-4-fluorophenyl)-7-ethoxy-6-nitroquinazoline-4-amine(1360430-70-1)
• EPA Substance Registry System: N-(3-chloro-4-fluorophenyl)-7-ethoxy-6-nitroquinazoline-4-amine(1360430-70-1)

Safety Data

• Hazardous Substances Data: 1360430-70-1(Hazardous Substances Data)

Upstream product

• 162012-70-6 4-chloro-7-fluoro-6-nitroquinazoline 
• 162012-69-3 7-fluoro-6-nitro-3H-quinazolin-4-one 
• 64-17-5 ethanol 
• 162012-67-1 N-(3-chloro-4-fluorophenyl)-7-fluoro-6-nitroquinazolin-4-amine 
• 141-52-6 sodium ethanolate 
• 89-77-0 2-Amino-4-chlorobenzoic acid 
• 936954-09-5 7-ethoxy-6-nitroquinazolin-4(1H)-one 
• 53449-14-2 7-Chloro-6-nitro-quinazolin-4-one 
• 31374-18-2 7-chloroquinazolin-4(1H)-one 
• 936954-10-8 4-chloro-7-ethoxy-6-nitroquinazoline 
• 367-21-5 3-chloro-4-fluorophenylamine 

Downstream Products

• 1360430-59-6 N-(4-(3-chloro-4-fluoroanilino)-7-ethoxyquinazolin-6-yl)acrylamide 
• 1360430-60-9 N-(4-(3-chloro-4-fluoroanilino)-7-ethoxyquinazolin-6-yl)-3-(dimethylamino)propanamide 
• 1360430-71-2 3-chloro-N-(4-(3-Chloro-4-fluoroanilino)-7-ethoxyquinazolin-6-yl)propanamide 
• 1360430-61-0 N-(4-(3-chloro-4-fluoroanilino)-7-ethoxyquinazolin-6-yl)-3-piperidin-1-ylpropanamide 
• 1360430-62-1 N-(4-((3-chloro-4-fluorophenyl)amino)-7-ethoxyquinazolin-6-yl)-3-morpholinopropanamide 
• 1269662-90-9 N⁴-(3-chloro-4-fluorophenyl)-7-ethoxyquinazoline-4,6-diamine 

Relevant articles and documents

PYRIMIDINE COMPOUNDS USEFUL AS TYROSINE KINASE INHIBITORS

The present disclosure provides pyrimidine compounds useful as tyrosine kinase inhibitors, and particularly epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 2 (HER2) inhibitors. The disclosed EGFR inhibitors are effective

Structure-activity study of quinazoline derivatives leading to the discovery of potent EGFR-T790M inhibitors

We have developed a series of 6, 7-disubstituted-4-(arylamino) quinazoline derivatives that functioned as irreversible EGFR inhibitors, and these compounds exhibited excellent enzyme inhibition potency. As compared with afatinib, some of them showed significantly enhanced activities towards H1975 cells (EGFR-T790M). Furthermore, the optimized compounds 7q and 8f also demonstrated good pharmacokinetic profiles, oral bioavailability as well as excellent in vivo efficacy in H1975 and HCC827 xenografts at a non-toxic dose. Based on the improved safety and efficacy against EGFR-T790M resistance, 7q and 8f are promising candidates for further studies.

FUNCTIONALIZED TYROSINE KINASE INHIBITORS MODIFIED WITH PRECIOUS METAL ELECTROPHILES AND METHODS ASSOCIATED THEREWITH

Newly synthesized thiourea-modified 3-chloro-4-fluoroanilio-quinazoline derivatives have been studied, as terminal carrier ligands in linear gold(I) complexes. The molecules mimic the tyrosine kinase inhibitor gefitinib (by computational docking experiments). Thiourea groups were either directly attached to quinazoline-C6 or linked to this position via a flexible ethylarmino chain. One compound tested acts as a thiourea-S/quinazoline-Nl mixed-donor ligand, giving an unusual dinuclear complex as determined by X-ray crystallography and/or electrospray mass spectrometry. One compound formed the desired stable linear complex. The biological activity of the carrier ligands and corresponding gold(I) complexes was studied in NCI-H460 and NCI-H1975 lung cancer cells. One compound that was tested partially overcomes resistance to gefitmib in NCI-H1975 (with IC50 values of 1.7 and 30 μΜ, respectively), and the corresponding gold complex (13) maintains activity in the low-micromolar concentration range.